Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-rwnhh Total loading time: 0 Render date: 2025-02-28T10:06:24.340Z Has data issue: false hasContentIssue false

1 - The Efficacy Story

Acute Mania; Rapid Cycling Bipolar Disorder; Bipolar II Disorder and Bipolar Depression; Bipolar Disorder Prophylaxis, Response Predictors; Unipolar Depression; Suicidality; Aggressive or Impulsive Behavior in Child/Adolescent Patients with Conduct Disorder, in Borderline Personality Disorder or in Patients with Intellectual Disability; Neuroprotective Properties; Elevation of Neutrophil Counts; Mechanisms of Action

Published online by Cambridge University Press:  09 February 2024

Jonathan M. Meyer  and
Stephen M. Stahl
Jonathan M. Meyer
Affiliation:
University of California, San Diego
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Acute Mania; Rapid Cycling Bipolar Disorder; Bipolar II Disorder and Bipolar Depression; Bipolar Disorder Prophylaxis, Response Predictors; Unipolar Depression; Suicidality; Aggressive or Impulsive Behavior in Child/Adolescent Patients with Conduct Disorder, in Borderline Personality Disorder or in Patients with Intellectual Disability; Neuroprotective Properties; Elevation of Neutrophil Counts; Mechanisms of Action

Type
Chapter
Information
The Lithium Handbook
Stahl's Handbooks
 , pp. 24 - 94
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Malhi, G. S., Gessler, D. and Outhred, T. (2017). The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines. J Affect Disord, 217, 266–280.CrossRefGoogle ScholarPubMed
Yatham, L. N., Kennedy, S. H., Parikh, S. V., et al. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord, 20, 97–170.CrossRefGoogle Scholar
McIntyre, R. S., Berk, M., Brietzke, E., et al. (2020). Bipolar disorders. Lancet, 396, 1841–1856.CrossRefGoogle ScholarPubMed
Fountoulakis, K. N., Tohen, M. and Zarate, C. A. (2022). Lithium treatment of bipolar disorder in adults: A systematic review of randomized trials and meta-analyses. Eur Neuropsychopharmacol, 54, 100–115.CrossRefGoogle ScholarPubMed
Poranen, J., Koistinaho, A., Tanskanen, A., et al. (2022). 20-year medication use trends in first-episode bipolar disorder. Acta Psychiatr Scand, 146, 583–593.CrossRefGoogle Scholar
Lahteenvuo, M., Tanskanen, A., Taipale, H., et al. (2018). Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry, 75, 347–355.CrossRefGoogle Scholar
Kook, K. A., Stimmel, G. L., Wilkins, J. N., et al. (1985). Accuracy and safety of a priori lithium loading. J Clin Psychiatry, 46, 49–51.Google ScholarPubMed
Keck, P. E., Jr., McElroy, S. L. and Bennett, J. A. (2000). Pharmacologic loading in the treatment of acute mania. Bipolar Disord, 2, 42–46.CrossRefGoogle ScholarPubMed
Cipriani, A., Barbui, C., Salanti, G., et al. (2005). Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis. Lancet, 378, 1306–1315.CrossRefGoogle Scholar
Sun, A. Y., Woods, S., Findling, R. L., et al. (2019). Safety considerations in the psychopharmacology of pediatric bipolar disorder. Expert Opin Drug Saf, 18, 777–794.CrossRefGoogle ScholarPubMed
Du, J., Quiroz, J., Yuan, P., et al. (2004). Bipolar disorder: Involvement of signaling cascades and AMPA receptor trafficking at synapses. Neuron Glia Biol, 1, 231–243.CrossRefGoogle ScholarPubMed
Meyer, J. M. (2022). Pharmacotherapy of psychosis and mania. In Brunton, L. L. and Knollmann, B. C., eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition. Chicago: McGraw-Hill, pp. 357–384.Google Scholar
Del’ Guidice, T. and Beaulieu, J. M. (2015). Selective disruption of dopamine D2-receptors/beta-arrestin2 signaling by mood stabilizers. J Recept Signal Transduct Res, 35, 224–232.CrossRefGoogle ScholarPubMed
O’Brien, W. T., Huang, J., Buccafusca, R., et al. (2011). Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest, 121, 3756–3762.CrossRefGoogle ScholarPubMed
Urs, N. M., Snyder, J. C., Jacobsen, J. P., et al. (2012). Deletion of GSK3β in D2 R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action. Proc Natl Acad Sci USA, 109, 20732–20737.CrossRefGoogle Scholar
Meyer, J. M. (2021). Approach to bipolar diathesis in schizophrenia spectrum patients. In Cummings, M. A. and Stahl, S. M., eds., Management of Complex Treatment-Resistant Psychotic Disorders (Stahl’s Handbooks). Cambridge: Cambridge University Press, pp. 42–50.Google Scholar
Schou, M. (2004). Lithium Treatment of Mood Disorders (6th edn.). Basle: S. Karger AG.CrossRefGoogle Scholar
Wingård, L., Brandt, L., Bodén, R., et al. (2019). Monotherapy vs. combination therapy for post mania maintenance treatment: A population based cohort study. Eur Neuropsychopharmacol, 29, 691–700.CrossRefGoogle ScholarPubMed
Tondo, L., Baldessarini, R. J. and Floris, G. (2001). Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry Suppl, 41, s184–190.CrossRefGoogle ScholarPubMed
Chakrabarty, T., Hadjipavlou, G., Bond, D. J., et al. (2019). Bipolar II disorder in context: A review of its epidemiology, disability and economic burden. In Parker, G., ed., Bipolar II Disorder: Modelling, Measuring and Managing (3rd edn.). Cambridge: Cambridge University Press, pp. 49–59.CrossRefGoogle Scholar
Öhlund, L., Ott, M., Bergqvist, M., et al. (2019). Clinical course and need for hospital admission after lithium discontinuation in patients with bipolar disorder type I or II: Mirror-image study based on the LiSIE retrospective cohort. BJPsych Open, 5, e101–112.CrossRefGoogle ScholarPubMed
Parker, G., Ricciardi, T., Tavella, G., et al. (2021). A single-blind randomized comparison of lithium and lamotrigine as maintenance treatments for managing bipolar II disorder. J Clin Psychopharmacol, 41, 381–388.CrossRefGoogle ScholarPubMed
Keck, P. E., Jr., McElroy, S. L., Strakowski, S. M., et al. (1994). Pharmacologic treatment of schizoaffective disorder. Psychopharmacology (Berl), 114, 529–538.CrossRefGoogle ScholarPubMed
Leucht, S., Helfer, B., Dold, M., et al. (2015). Lithium for schizophrenia. Cochrane Database Syst Rev, Cd003834.CrossRefGoogle Scholar
Puranen, A., Koponen, M., Lahteenvuo, M., et al. (2022). Real-world effectiveness of mood stabilizer use in schizophrenia. Acta Psychiatr Scand, 147, 257–266.CrossRefGoogle Scholar
Lintunen, J., Taipale, H., Tanskanen, A., et al. (2021). Long-term real-world effectiveness of pharmacotherapies for schizoaffective disorder. Schizophr Bull, 47, 1099–1107.CrossRefGoogle ScholarPubMed
Judd, L. L., Akiskal, H. S., Schettler, P. J., et al. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry, 59, 530–537.CrossRefGoogle ScholarPubMed
Judd, L. L., Akiskal, H. S., Schettler, P. J., et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry, 60, 261–269.CrossRefGoogle ScholarPubMed
Amsterdam, J. D., Lorenzo-Luaces, L., Soeller, I., et al. (2016). Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: Effectiveness and mood conversion rate. Br J Psychiatry, 208, 359–365.CrossRefGoogle ScholarPubMed
Hui, T. P., Kandola, A., Shen, L., et al. (2019). A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder. Acta Psychiatr Scand, 140, 94–115.CrossRefGoogle ScholarPubMed
Strawbridge, R., Kurana, S., Kerr-Gaffney, J., et al. (2022). A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder. Acta Psychiatr Scand, 146, 290–311.CrossRefGoogle ScholarPubMed
Baldessarini, R. J., Tondo, L., Floris, G., et al. (2000). Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. J Affect Disord, 61, 13–22.CrossRefGoogle ScholarPubMed
Calabrese, J. R., Shelton, M. D., Rapport, D. J., et al. (2005). A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry, 162, 2152–2161.CrossRefGoogle ScholarPubMed
Kemp, D. E., Gao, K., Ganocy, S. J., et al. (2009). A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and co-occurring substance abuse or dependence. J Clin Psychiatry, 70, 113–121.CrossRefGoogle ScholarPubMed
Zhihan, G., Fengli, S., Wangqiang, L., et al. (2022). Lamotrigine and lithium combination for treatment of rapid cycling bipolar disorder: Results from meta-analysis. Front Psychiatry, 13, 913051.CrossRefGoogle ScholarPubMed
Baldessarini, R. J. and Tondo, L. (2021). Testing for antisuicidal effects of lithium treatment. JAMA Psychiatry, 79, 9–10.CrossRefGoogle Scholar
Weisler, R. H., Nolen, W. A., Neijber, A., et al. (2011). Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: A randomized controlled study). J Clin Psychiatry, 72, 1452–1464.CrossRefGoogle ScholarPubMed
Young, A. H., McElroy, S. L., Bauer, M., et al. (2010). A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry, 71, 150–162.CrossRefGoogle ScholarPubMed
Calabrese, J. R., Bowden, C. L., Sachs, G., et al. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry, 64, 1013–1024.CrossRefGoogle ScholarPubMed
Katz, I. R., Rogers, M. P., Lew, R., et al. (2022). Lithium treatment in the prevention of repeat suicide-related outcomes in veterans with major depression or bipolar disorder: A randomized clinical trial. JAMA Psychiatry, 79, 24–32.CrossRefGoogle ScholarPubMed
Baldessarini, R. J., Tondo, L., Davis, P., et al. (2006). Decreased risk of suicides and attempts during long-term lithium treatment: A meta-analytic review. Bipolar Disord, 8, 625–639.CrossRefGoogle ScholarPubMed
Smith, K. A. and Cipriani, A. (2017). Lithium and suicide in mood disorders: Updated meta-review of the scientific literature. Bipolar Disord, 19, 575–586.CrossRefGoogle ScholarPubMed
Baldessarini, R. J., Tondo, L. and Vazquez, G. H. (2019). Pharmacological treatment of adult bipolar disorder. Mol Psychiatry, 24, 198–217.CrossRefGoogle ScholarPubMed
Velosa, J., Delgado, A., Finger, E., et al. (2020). Risk of dementia in bipolar disorder and the interplay of lithium: A systematic review and meta-analyses. Acta Psychiatr Scand, 141, 510–521.CrossRefGoogle ScholarPubMed
Barjasteh-Askari, F., Davoudi, M., Amini, H., et al. (2020). Relationship between suicide mortality and lithium in drinking water: A systematic review and meta-analysis. J Affect Disord, 264, 234–241.CrossRefGoogle ScholarPubMed
Del Matto, L., Muscas, M., Murru, A., et al. (2020). Lithium and suicide prevention in mood disorders and in the general population: A systematic review. Neurosci Biobehav Rev, 116, 142–153.CrossRefGoogle ScholarPubMed
Kugimiya, T., Ishii, N., Kohno, K., et al. (2021). Lithium in drinking water and suicide prevention: The largest nationwide epidemiological study from Japan. Bipolar Disord, 23, 33–40.CrossRefGoogle ScholarPubMed
Forlenza, O. V., Radanovic, M., Talib, L. L., et al. (2019). Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: Randomised clinical trial. Br J Psychiatry, 215, 668–674.CrossRefGoogle ScholarPubMed
Undurraga, J., Sim, K., Tondo, L., et al. (2019). Lithium treatment for unipolar major depressive disorder: Systematic review. J Psychopharmacol, 33, 167–176.CrossRefGoogle ScholarPubMed
Nierenberg, A. A., Fava, M., Trivedi, M. H., et al. (2006). A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report. Am J Psychiatry, 163, 1519–1530.CrossRefGoogle Scholar
Vázquez, G. H., Bahji, A., Undurraga, J., et al. (2021). Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs. esketamine vs. lithium. J Psychopharmacol, 35, 890–900.CrossRefGoogle ScholarPubMed
Muller-Oerlinghausen, B. and Lewitzka, U. (2010). Lithium reduces pathological aggression and suicidality: A mini-review. Neuropsychobiology, 62, 43–49.CrossRefGoogle ScholarPubMed
Giotakos, O. (2018). Is violence in part a lithium deficiency state? Pschiatriki, 29, 264–270.CrossRefGoogle Scholar
Masi, G., Milone, A., Manfredi, A., et al. (2009). Effectiveness of lithium in children and adolescents with conduct disorder: A retrospective naturalistic study. CNS Drugs, 23, 59–69.CrossRefGoogle ScholarPubMed
Pringsheim, T., Hirsch, L., Gardner, D., et al. (2015). The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. Part 2: Antipsychotics and traditional mood stabilizers. Can J Psychiatry, 60, 52–61.CrossRefGoogle ScholarPubMed
Deb, S., Chaplin, R., Sohanpal, S., et al. (2008). The effectiveness of mood stabilizers and antiepileptic medication for the management of behaviour problems in adults with intellectual disability: A systematic review. J Intellect Disabil Res, 52, 107–113.CrossRefGoogle ScholarPubMed
Ji, N. Y. and Findling, R. L. (2016). Pharmacotherapy for mental health problems in people with intellectual disability. Curr Opin Psychiatry, 29, 103–125.CrossRefGoogle ScholarPubMed
Stone, M. H. (2022). Borderline personality disorder: Clinical guidelines for treatment. Psychodyn Psychiatry, 50, 45–63.CrossRefGoogle ScholarPubMed
Steiner, T. J., Hering, R., Couturier, E. G., et al. (1997). Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia, 17, 673–675.CrossRefGoogle ScholarPubMed
Kwon, J. H., Han, J. Y., Choi, J. W., et al. (2022). Comparative impact of pharmacological therapies on cluster headache management: A systematic review and network meta-analysis. J Clin Med, 11, 1–20.CrossRefGoogle ScholarPubMed
Mattai, A., Fung, L., Bakalar, J., et al. (2009). Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children. Hum Psychopharmacol, 24, 584–589.CrossRefGoogle ScholarPubMed
Nykiel, S., Henderson, D., Bhide, G., et al. (2010). Lithium to allow clozapine prescribing in benign ethnic neutropenia. Clin Schizophr Relat Psychoses, 4, 138–140.CrossRefGoogle ScholarPubMed
Rothstein, G., Clarkson, D. R., Larsen, W., et al. (1978). Effect of lithium on neutrophil mass and production. N Engl J Med, 298, 178–180.CrossRefGoogle ScholarPubMed
Focosi, D., Azzara, A., Kast, R. E., et al. (2009). Lithium and hematology: Established and proposed uses. J Leukoc Biol, 85, 20–28.CrossRefGoogle ScholarPubMed
Petrini, M. and Azzara, A. (2012). Lithium in the treatment of neutropenia. Curr Opin Hematol, 19, 52–57.CrossRefGoogle ScholarPubMed
Phiel, C. J. and Klein, P. S. (2001). Molecular targets of lithium action. Annu Rev Pharmacol Toxicol, 41, 789–813.CrossRefGoogle ScholarPubMed
Pasquali, L., Busceti, C. L., Fulceri, F., et al. (2010). Intracellular pathways underlying the effects of lithium. Behav Pharmacol, 21, 473–492.CrossRefGoogle ScholarPubMed
Bellivier, F. and Marie-Claire, C. (2018). Molecular signatures of lithium treatment: Current knowledge. Pharmacopsychiatry, 51, 212–219.Google ScholarPubMed
Scott, J., Hidalgo-Mazzei, D., Strawbridge, R., et al. (2019). Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: Overview of the H2020-funded R-LiNK initiative. Int J Bipolar Disord, 7, 20.CrossRefGoogle ScholarPubMed
Hou, L., Heilbronner, U., Degenhardt, F., et al. (2016). Genetic variants associated with response to lithium treatment in bipolar disorder: A genome-wide association study. Lancet, 387, 1085–1093.CrossRefGoogle ScholarPubMed
Scott, J., Geoffroy, P. A., Sportiche, S., et al. (2017). Cross-validation of clinical characteristics and treatment patterns associated with phenotypes for lithium response defined by the Alda scale. J Affect Disord, 208, 62–67.CrossRefGoogle ScholarPubMed
Scott, J., Etain, B. and Bellivier, F. (2018). Can an integrated science approach to precision medicine research improve lithium treatment in bipolar disorders? Front Psychiatry, 9, 360.CrossRefGoogle ScholarPubMed
McCarthy, M. J., Wei, H., Nievergelt, C. M., et al. (2019). Chronotype and cellular circadian rhythms predict the clinical response to lithium maintenance treatment in patients with bipolar disorder. Neuropsychopharmacology, 44, 620–628.CrossRefGoogle ScholarPubMed
Lin, Y., Maihofer, A. X., Stapp, E., et al. (2021). Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. Bipolar Disord, 23, 821–831.CrossRefGoogle ScholarPubMed
Mishra, H. K., Ying, N. M., Luis, A., et al. (2021). Circadian rhythms in bipolar disorder patient-derived neurons predict lithium response: Preliminary studies. Mol Psychiatry, 26, 3383–3394.CrossRefGoogle ScholarPubMed
Grunze, H., Vieta, E., Goodwin, G. M., et al. (2009). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2009 on the treatment of acute mania. World J Biol Psychiatry, 10, 85–116.CrossRefGoogle ScholarPubMed
Grunze, H., Vieta, E., Goodwin, G. M., et al. (2010). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry, 11, 81–109.CrossRefGoogle ScholarPubMed
Bauer, M., Pfennig, A., Severus, E., et al. (2013). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry, 14, 334–385.CrossRefGoogle ScholarPubMed
Grunze, H., Vieta, E., Goodwin, G. M., et al. (2013). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry, 14, 154–219.CrossRefGoogle ScholarPubMed
Grunze, H., Vieta, E., Goodwin, G. M., et al. (2018). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry, 19, 2–58.CrossRefGoogle ScholarPubMed
Malhi, G. S., Bell, E., Bassett, D., et al. (2021). The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry, 55, 7–117.CrossRefGoogle ScholarPubMed
Fountoulakis, K. N., Grunze, H., Vieta, E., et al. (2017). The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), Part 3: The clinical guidelines. Int J Neuropsychopharmacol, 20, 180–195.Google ScholarPubMed
Fountoulakis, K. N., Yatham, L., Grunze, H., et al. (2017). The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), Part 2: Review, grading of the evidence, and a precise algorithm. Int J Neuropsychopharmacol, 20, 121–179.Google Scholar
Fountoulakis, K. N., Yatham, L. N., Grunze, H., et al. (2020). The CINP guidelines on the definition and evidence-based interventions for treatment-resistant bipolar disorder. Int J Neuropsychopharmacol, 23, 230–256.CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence (2020). Bipolar disorder guidelines (NICE CG185): 2020 amendment: nice.org.uk/guidance/cg185.Google Scholar
Schou, M., Juel-Nielsen, N., Stromgren, E., et al. (1954). The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry, 17, 250–260.CrossRefGoogle ScholarPubMed
Schou, M. (1999). The early European lithium studies. Aust N Z J Psychiatry, 33 Suppl., S39–47.CrossRefGoogle ScholarPubMed
Bowden, C. L., Brugger, A. M., Swann, A. C., et al. (1994). Efficacy of divalproex vs lithium and placebo in the treatment of mania: The Depakote Mania Study Group. JAMA, 271, 918–924.CrossRefGoogle ScholarPubMed
Bowden, C. L., Grunze, H., Mullen, J., et al. (2005). A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry, 66, 111–121.CrossRefGoogle ScholarPubMed
Kushner, S. F., Khan, A., Lane, R., et al. (2006). Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo-controlled trials. Bipolar Disord, 8, 15–27.CrossRefGoogle ScholarPubMed
Keck, P. E., Orsulak, P. J., Cutler, A. J., et al. (2009). Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord, 112, 36–49.CrossRefGoogle Scholar
Rosenblat, J. D. and McIntyre, R. S. (2017). Treatment of mixed features in bipolar disorder. CNS Spectr, 22, 141–146.CrossRefGoogle ScholarPubMed
McKnight, R. F., de La Motte de Broons de Vauvert, S., Chesney, E., et al. (2019). Lithium for acute mania. Cochrane Database Syst Rev, 6, Cd004048.Google ScholarPubMed
Cade, J. F. J. (1949). Lithium salts in the treatment of psychotic excitement. Medical J Aust, 36, 349–351.CrossRefGoogle Scholar
Castro, V. M., Roberson, A. M., McCoy, T. H., et al. (2016). Stratifying risk for renal insufficiency among lithium-treated patients: An electronic health record study. Neuropsychopharmacology, 41, 1138–1143.CrossRefGoogle ScholarPubMed
Reischies, F. M., Hartikainen, J. and Berghöfer, A. (2002). Initial lithium and valproate combination therapy in acute mania. Neuropsychobiology, 46 Suppl. 1, 22–27.CrossRefGoogle ScholarPubMed
Kishi, T., Ikuta, T., Matsuda, Y., et al. (2021). Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: A systematic review and network meta-analysis of randomized controlled trials. Mol Psychiatry, 26, 4146–4157.CrossRefGoogle ScholarPubMed
Dunner, D. L. and Fieve, R. R. (1974). Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry, 30, 229–233.CrossRefGoogle ScholarPubMed
Association, American Psychiatric (2022). Diagnostic & Statistical Manual of Mental Disorders Fifth Edition –Text Revision. Washington, DC: American Psychiatric Press, Inc.CrossRefGoogle Scholar
Sachs, G. S., Thase, M. E., Otto, M. W., et al. (2003). Rationale, design, and methods of the Systematic Treatment Enhancement Program for bipolar disorder (STEP-BD). Biol Psychiatry, 53, 1028–1042.CrossRefGoogle ScholarPubMed
Schneck, C. D., Miklowitz, D. J., Calabrese, J. R., et al. (2004). Phenomenology of rapid-cycling bipolar disorder: Data from the first 500 participants in the Systematic Treatment Enhancement Program. Am J Psychiatry, 161, 1902–1908.CrossRefGoogle ScholarPubMed
Fountoulakis, K. N., Kontis, D., Gonda, X., et al. (2013). A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Disord, 15, 115–137.CrossRefGoogle ScholarPubMed
Kohler, S., Friedel, E. and Stamm, T. (2017). [Rapid cycling in bipolar disorders: Symptoms, background and treatment recommendations]. Fortschr Neurol Psychiatr, 85, 199–211.Google ScholarPubMed
Nunes, A., Ardau, R., Berghofer, A., et al. (2020). Prediction of lithium response using clinical data. Acta Psychiatr Scand, 141, 131–141.CrossRefGoogle ScholarPubMed
Allain, N., Leven, C., Falissard, B., et al. (2017). Manic switches induced by antidepressants: An umbrella review comparing randomized controlled trials and observational studies. Acta Psychiatr Scand, 135, 106–116.CrossRefGoogle ScholarPubMed
Doane, M. J., Bessonova, L., Friedler, H. S., et al. (2022). Weight gain and comorbidities associated with oral second-generation antipsychotics: Analysis of real-world data for patients with schizophrenia or bipolar I disorder. BMC Psychiatry, 22, 114–125.CrossRefGoogle ScholarPubMed
Leverich, G. S., Altshuler, L. L., Frye, M. A., et al. (2006). Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry, 163, 232–239.CrossRefGoogle ScholarPubMed
Altshuler, L. L., Sugar, C. A., McElroy, S. L., et al. (2017). Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: A randomized double-blind comparison. Am J Psychiatry, 174, 266–276.CrossRefGoogle ScholarPubMed
Greil, W. and Kleindienst, N. (1999). Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol, 14, 283–285.CrossRefGoogle Scholar
GlaxoSmithKline LLC (2022). Lamictal package insert. Research Triangle Park, NC.Google Scholar
Bunschoten, J. W., Husein, N., Devinsky, O., et al. (2022). Sudden death and cardiac arrythmia with lamotrigine: A rapid systematic review. Neurology, 98, e1748–e1760.CrossRefGoogle ScholarPubMed
Bowden, C. L., Calabrese, J. R., McElroy, S. L., et al. (2000). A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder: Divalproex Maintenance Study Group. Arch Gen Psychiatry, 57, 481–489.CrossRefGoogle ScholarPubMed
Bowden, C. L., Calabrese, J. R., Sachs, G., et al. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry, 60, 392–400.CrossRefGoogle ScholarPubMed
Deb, S., Austin, P. C., Tu, J. V., et al. (2016). A review of propensity-score methods and their use in cardiovascular research. Can J Cardiol, 32, 259–265.CrossRefGoogle ScholarPubMed
Hayes, J. F., Marston, L., Walters, K., et al. (2016). Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: A population-based UK cohort study using electronic health records. World Psychiatry, 15, 53–58.CrossRefGoogle ScholarPubMed
Aiff, H., Attman, P.-O., Aurell, M., et al. (2014). The impact of modern treatment principles may have eliminated lithium-induced renal failure. J Psychopharmacol, 28, 151–154.CrossRefGoogle ScholarPubMed
Nolen, W. A., Licht, R. W., Young, A. H., et al. (2019). What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. Bipolar Disord, 21, 394–409.CrossRefGoogle ScholarPubMed
Schoot, T. S., Molmans, T. H. J., Grootens, K. P., et al. (2020). Systematic review and practical guideline for the prevention and management of the renal side effects of lithium therapy. Eur Neuropsychopharmacol, 31, 16–32.CrossRefGoogle ScholarPubMed
Clos, S., Rauchhaus, P., Severn, A., et al. (2015). Long-term effect of lithium maintenance therapy on estimated glomerular filtration rate in patients with affective disorders: A population-based cohort study. Lancet Psychiatry, 2, 1075–1083.CrossRefGoogle Scholar
Kessing, L. V., Gerds, T. A., Feldt-Rasmussen, B., et al. (2015). Use of lithium and anticonvulsants and the rate of chronic kidney disease: A nationwide population-based study. JAMA Psychiatry, 72, 1182–1191.CrossRefGoogle ScholarPubMed
Fransson, F., Werneke, U., Harju, V., et al. (2022). Kidney function in patients with bipolar disorder with and without lithium treatment compared with the general population in northern Sweden: Results from the LiSIE and MONICA cohorts. Lancet Psychiatry, 9, 804–814.CrossRefGoogle ScholarPubMed
Kessing, L. V., Hellmund, G. and Andersen, P. K. (2011). Predictors of excellent response to lithium: Results from a nationwide register-based study. Int Clin Psychopharmacol, 26, 323–328.CrossRefGoogle ScholarPubMed
Grillault Laroche, D., Etain, B., Severus, E., et al. (2020). Socio-demographic and clinical predictors of outcome to long-term treatment with lithium in bipolar disorders: A systematic review of the contemporary literature and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. Int J Bipolar Disord, 8, 1–13.CrossRefGoogle ScholarPubMed
Scott, J., Bellivier, F., Manchia, M., et al. (2020). Can network analysis shed light on predictors of lithium response in bipolar I disorder? Acta Psychiatr Scand, 141, 522–533.CrossRefGoogle ScholarPubMed
Calabrese, J. R., Suppes, T., Bowden, C. L., et al. (2000). A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder: Lamictal 614 Study Group. J Clin Psychiatry, 61, 841–850.CrossRefGoogle ScholarPubMed
Baldessarini, R. J., Tondo, L., Baethge, C. J., et al. (2007). Effects of treatment latency on response to maintenance treatment in manic-depressive disorders. Bipolar Disord, 9, 386–393.CrossRefGoogle ScholarPubMed
Bratti, I. M., Baldessarini, R. J., Baethge, C., et al. (2003). Pretreatment episode count and response to lithium treatment in manic-depressive illness. Harv Rev Psychiatry, 11, 245–256.CrossRefGoogle ScholarPubMed
Kessing, L. V., Vradi, E. and Andersen, P. K. (2014). Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry, 205, 214–220.CrossRefGoogle ScholarPubMed
Januel, D., Poirier, M. F., D’Alche-Biree, F., et al. (2003). Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. J Affect Disord, 76, 191–200.CrossRefGoogle ScholarPubMed
Chenu, F. and Bourin, M. (2006). Potentiation of antidepressant-like activity with lithium: Mechanism involved. Curr Drug Targets, 7, 159–163.CrossRefGoogle ScholarPubMed
Nelson, J. C., Baumann, P., Delucchi, K., et al. (2014). A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord, 168, 269–275.CrossRefGoogle ScholarPubMed
Gerhard, T., Stroup, T. S., Correll, C. U., et al. (2020). Mortality risk of antipsychotic augmentation for adult depression. PLoS One, 15, e0239206.CrossRefGoogle ScholarPubMed
Katz, I. R., Ferguson, R. E. and Liang, M. H. (2022). Suicide risk and lithium-reply. JAMA Psychiatry, 79, 513–514.CrossRefGoogle ScholarPubMed
Tondo, L., Hennen, J. and Baldessarini, R. J. (2001). Lower suicide risk with long-term lithium treatment in major affective illness: A meta-analysis. Acta Psychiatr Scand, 104, 163–172.CrossRefGoogle ScholarPubMed
Vita, A., De Peri, L. and Sacchetti, E. (2015). Lithium in drinking water and suicide prevention: A review of the evidence. Int Clin Psychopharmacol, 30, 1–5.CrossRefGoogle ScholarPubMed
Eyre-Watt, B., Mahendran, E., Suetani, S., et al. (2021). The association between lithium in drinking water and neuropsychiatric outcomes: A systematic review and meta-analysis from across 2678 regions containing 113 million people. Aust N Z J Psychiatry, 55, 139–152.CrossRefGoogle ScholarPubMed
Araya, P., Martínez, C. and Barros, J. (2022). Lithium in drinking water as a public policy for suicide prevention: Relevance and considerations. Front Public Health, 10, 805774.CrossRefGoogle ScholarPubMed
Kawada, T. (2022). Lithium in drinking water and suicide: A sex difference and dose-response relationship. Bipolar Disord, 24, 207–208.CrossRefGoogle ScholarPubMed
Liaugaudaite, V., Raskauskiene, N., Naginiene, R., et al. (2022). Association between lithium levels in drinking water and suicide rates: Role of affective disorders. J Affect Disord, 298, 516–521.CrossRefGoogle ScholarPubMed
Hayes, J. F., Pitman, A., Marston, L., et al. (2016). Self-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: A UK population-based electronic health records study. JAMA Psychiatry, 73, 630–637.CrossRefGoogle ScholarPubMed
Song, J., Sjolander, A., Joas, E., et al. (2017). Suicidal behavior during lithium and valproate treatment: A within-individual 8-year prospective study of 50,000 patients with bipolar disorder. Am J Psychiatry, 174, 795–802.CrossRefGoogle Scholar
Calabresi, P., Pisani, A., Mercuri, N. B., et al. (1993). Lithium treatment blocks long-term synaptic depression in the striatum. Neuron, 10, 955–962.CrossRefGoogle ScholarPubMed
Nonaka, S. and Chuang, D. M. (1998). Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport, 9, 2081–2084.CrossRefGoogle ScholarPubMed
Nonaka, S., Hough, C. J. and Chuang, D. M. (1998). Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA, 95, 2642–2647.CrossRefGoogle ScholarPubMed
Nonaka, S., Katsube, N. and Chuang, D. M. (1998). Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine. J Pharmacol Exp Ther, 286, 539–547.Google ScholarPubMed
Almeida, O. P., Singulani, M. P., Ford, A. H., et al. (2022). Lithium and stroke recovery: A systematic review and meta-analysis of stroke models in rodents and human data. Stroke, 53, 2935–2944.CrossRefGoogle ScholarPubMed
Nunes, M. A., Schowe, N. M., Monteiro-Silva, K. C., et al. (2015). Chronic microdose lithium treatment prevented memory loss and neurohistopathological changes in a transgenic mouse model of Alzheimer’s disease. PLoS One, 10, e0142267.CrossRefGoogle Scholar
Morris, G. and Berk, M. (2016). The putative use of lithium in Alzheimer’s Disease. Curr Alzheimer Res, 13, 853–861.CrossRefGoogle ScholarPubMed
Haupt, M., Bahr, M. and Doeppner, T. R. (2021). Lithium beyond psychiatric indications: The reincarnation of a new old drug. Neural Regen Res, 16, 2383–2387.Google ScholarPubMed
Rybakowski, J. K. (2016). Effect of lithium on neurocognitive functioning. Curr Alzheimer Res, 13, 887–893.CrossRefGoogle ScholarPubMed
Kessing, L. V., Gerds, T. A., Knudsen, N. N., et al. (2017). Association of lithium in drinking water with the incidence of dementia. JAMA Psychiatry, 74, 1005–1010.CrossRefGoogle ScholarPubMed
Parker, W. F., Gorges, R. J., Gao, Y. N., et al. (2018). Association between groundwater lithium and the diagnosis of bipolar disorder and dementia in the United States. JAMA Psychiatry, 75, 751–754.CrossRefGoogle ScholarPubMed
Van Gestel, H., Franke, K., Petite, J., et al. (2019). Brain age in bipolar disorders: Effects of lithium treatment. Aust N Z J Psychiatry, 53, 1179–1188.CrossRefGoogle ScholarPubMed
Chen, S., Underwood, B. R., Jones, P. B., et al. (2022). Association between lithium use and the incidence of dementia and its subtypes: A retrospective cohort study. PLoS Med, 19, e1003941.CrossRefGoogle ScholarPubMed
Rej, S., Yu, C., Shulman, K., et al. (2015). Medical comorbidity, acute medical care use in late-life bipolar disorder: A comparison of lithium, valproate, and other pharmacotherapies. Gen Hosp Psychiatry, 37, 528–532.CrossRefGoogle ScholarPubMed
Abé, C., Liberg, B., Song, J., et al. (2020). Longitudinal cortical thickness changes in bipolar disorder and the relationship to genetic risk, mania, and lithium use. Biol Psychiatry, 87, 271–281.CrossRefGoogle ScholarPubMed
Beunders, A. J. M., Kemp, T., Korten, N. C. M., et al. (2021). Cognitive performance in older-age bipolar disorder: Investigating psychiatric characteristics, cardiovascular burden and psychotropic medication. Acta Psychiatr Scand, 144, 392–406.CrossRefGoogle ScholarPubMed
Ballester, P. L., Romano, M. T., de Azevedo Cardoso, T., et al. (2022). Brain age in mood and psychotic disorders: A systematic review and meta-analysis. Acta Psychiatr Scand, 145, 42–55.CrossRefGoogle ScholarPubMed
Lewandowski, K. E., Sperry, S. H., Malloy, M. C., et al. (2014). Age as a predictor of cognitive decline in bipolar disorder. Am J Geriatr Psychiatry, 22, 1462–1468.CrossRefGoogle ScholarPubMed
Easter, R. E., Ryan, K. A., Estabrook, R., et al. (2022). Limited time-specific and longitudinal effects of depressive and manic symptoms on cognition in bipolar spectrum disorders. Acta Psychiatr Scand, 146, 430–441.CrossRefGoogle ScholarPubMed
Gerhard, T., Devanand, D. P., Huang, C., et al. (2015). Lithium treatment and risk for dementia in adults with bipolar disorder: Population-based cohort study. Br J Psychiatry, 207, 46–51.CrossRefGoogle ScholarPubMed
Juurlink, D. N., Mamdani, M. M., Kopp, A., et al. (2004). Drug-induced lithium toxicity in the elderly: A population-based study. J Am Geriatr Soc, 52, 794–798.CrossRefGoogle ScholarPubMed
Heath, L. J., Billups, S. J., Gaughan, K. M., et al. (2018). Risk factors for utilization of acute care services for lithium toxicity. Psychiatr Serv, 69, 671–676.CrossRefGoogle ScholarPubMed
Golic, M., Aiff, H., Attman, P. O., et al. (2021). Starting lithium in patients with compromised renal function – is it wise? J Psychopharmacol, 35, 190–197.CrossRefGoogle ScholarPubMed
Wingo, A. P., Wingo, T. S., Harvey, P. D., et al. (2009). Effects of lithium on cognitive performance: A meta-analysis. J Clin Psychiatry, 70, 1588–1597.CrossRefGoogle ScholarPubMed
Paterson, A. and Parker, G. (2017). Lithium and cognition in those with bipolar disorder. Int Clin Psychopharmacol, 32, 57–62.CrossRefGoogle ScholarPubMed
Burdick, K. E., Millett, C. E., Russo, M., et al. (2020). The association between lithium use and neurocognitive performance in patients with bipolar disorder. Neuropsychopharmacology, 45, 1743–1749.CrossRefGoogle ScholarPubMed
Forlenza, O. V., Hajek, T., Almeida, O. P., et al. (2022). Demographic and clinical characteristics of lithium-treated older adults with bipolar disorder. Acta Psychiatr Scand, 146, 442–455.CrossRefGoogle ScholarPubMed
Patra, S. (2020). A salt for preventing Alzheimer’s? Lithium seems to be! Aust N Z J Psychiatry, 54, 109–110.CrossRefGoogle ScholarPubMed
Puglisi-Allegra, S., Ruggieri, S. and Fornai, F. (2021). Translational evidence for lithium-induced brain plasticity and neuroprotection in the treatment of neuropsychiatric disorders. Transl Psychiatry, 11, 366.CrossRefGoogle ScholarPubMed
Ochoa, E. L. M. (2022). Lithium as a neuroprotective agent for bipolar disorder: An overview. Cell Mol Neurobiol, 42, 85–97.CrossRefGoogle ScholarPubMed
Coutts, F., Palmos, A. B., Duarte, R. R. R., et al. (2019). The polygenic nature of telomere length and the anti-ageing properties of lithium. Neuropsychopharmacology, 44, 757–765.CrossRefGoogle ScholarPubMed
Martinsson, L., Wei, Y., Xu, D., et al. (2013). Long-term lithium treatment in bipolar disorder is associated with longer leukocyte telomeres. Transl Psychiatry, 3, e261.CrossRefGoogle ScholarPubMed
Powell, T. R., Dima, D., Frangou, S., et al. (2018). Telomere length and bipolar disorder. Neuropsychopharmacology, 43, 445–453.CrossRefGoogle ScholarPubMed
Squassina, A., Pisanu, C., Congiu, D., et al. (2016). Leukocyte telomere length positively correlates with duration of lithium treatment in bipolar disorder patients. Eur Neuropsychopharmacol, 26, 1241–1247.CrossRefGoogle ScholarPubMed
Lundberg, M., Biernacka, J. M., Lavebratt, C., et al. (2020). Expression of telomerase reverse transcriptase positively correlates with duration of lithium treatment in bipolar disorder. Psychiatry Res, 286, 112865.CrossRefGoogle ScholarPubMed
Schrauzer, G. N. and Shrestha, K. P. (1990). Lithium in drinking water and the incidences of crimes, suicides, and arrests related to drug addictions. Biol Trace Elem Res, 25, 105–113.CrossRefGoogle ScholarPubMed
Giotakos, O., Nisianakis, P., Tsouvelas, G., et al. (2013). Lithium in the public water supply and suicide mortality in Greece. Biol Trace Elem Res, 156, 376–379.CrossRefGoogle ScholarPubMed
Giotakos, O., Tsouvelas, G., Nisianakis, P., et al. (2015). A negative association between lithium in drinking water and the incidences of homicides, in Greece. Biol Trace Elem Res, 164, 165–168.CrossRefGoogle ScholarPubMed
Quanbeck, C. D., McDermott, B. E., Lam, J., et al. (2007). Categorization of aggressive acts committed by chronically assaultive state hospital patients. Psychiatr Serv, 58, 521–528.CrossRefGoogle ScholarPubMed
Volavka, J. and Citrome, L. (2008). Heterogeneity of violence in schizophrenia and implications for long-term treatment. International Journal of Clinical Practice, 62, 1237–1245.CrossRefGoogle ScholarPubMed
Brown, D., Larkin, F., Sengupta, S., et al. (2014). Clozapine: An effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital. CNS Spectr, 19, 391–402.CrossRefGoogle Scholar
Campbell, M., Adams, P. B., Small, A. M., et al. (1995). Lithium in hospitalized aggressive children with conduct disorder: A double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry, 34, 445–453.CrossRefGoogle ScholarPubMed
Malone, R. P., Delaney, M. A., Luebbert, J. F., et al. (2000). A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry, 57, 649–654.CrossRefGoogle ScholarPubMed
Stoffers, J., Völlm, B. A., Rücker, G., et al. (2010). Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev, Cd005653.CrossRefGoogle Scholar
Mercer, D., Douglass, A. B. and Links, P. S. (2009). Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: Effectiveness for depression and anger symptoms. J Pers Disord, 23, 156–174.CrossRefGoogle ScholarPubMed
Bellino, S., Rinaldi, C., Bozzatello, P., et al. (2011). Pharmacotherapy of borderline personality disorder: A systematic review for publication purpose. Curr Med Chem, 18, 3322–3329.CrossRefGoogle ScholarPubMed
Pulcu, E., Saunders, K. E. A., Harmer, C. J., et al. (2022). Using a generative model of affect to characterize affective variability and its response to treatment in bipolar disorder. Proc Natl Acad Sci USA, 119, e2202983119.CrossRefGoogle ScholarPubMed
Janowsky, D. S., Soares, J., Hatch, J. P., et al. (2009). Lithium effect on renal glomerular function in individuals with intellectual disability. J Clin Psychopharmacol, 29, 296–299.CrossRefGoogle ScholarPubMed
Janowsky, D. S., Buneviciute, J., Hu, Q., et al. (2011). Lithium-induced renal insufficiency – a longitudinal study of creatinine increases in intellectually disabled adults. J Clin Psychopharmacol, 31, 769–773.CrossRefGoogle ScholarPubMed
Yuan, J., Song, J., Zhu, D., et al. (2018). Lithium treatment is safe in children with intellectual disability. Front Mol Neurosci, 11, 425.CrossRefGoogle ScholarPubMed
Oliver-Africano, P., Dickens, S., Ahmed, Z., et al. (2010). Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities. J Intellect Disabil Res, 54, 17–25.CrossRefGoogle ScholarPubMed
Ballin, A., Lehman, D., Sirota, P., et al. (1998). Increased number of peripheral blood CD34+ cells in lithium-treated patients. Br J Haematol, 100, 219–221.CrossRefGoogle ScholarPubMed
Acharya, S. and Bussel, J. B. (2000). Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol, 22, 62–65.CrossRefGoogle ScholarPubMed
Malik, S., Lally, J., Ajnakina, O., et al. (2018). Sodium valproate and clozapine induced neutropenia: A case control study using register data. Schizophr Res, 195, 267–273.CrossRefGoogle ScholarPubMed
Jones, G. H., Rong, C., Shariq, A. S., et al. (2021). Intracellular signaling cascades in bipolar disorder. Curr Top Behav Neurosci, 48, 101–132.CrossRefGoogle ScholarPubMed
Campbell, I. H., Campbell, H. and Smith, D. J. (2022). Insulin signaling as a therapeutic mechanism of lithium in bipolar disorder. Transl Psychiatry, 12, 350.CrossRefGoogle ScholarPubMed
Tye, S. J., Borreggine, K., Price, J. B., et al. (2022). Dynamic insulin-stimulated mTOR/GSK3 signaling in peripheral immune cells: Preliminary evidence for an association with lithium response in bipolar disorder. Bipolar Disord, 24, 39–47.CrossRefGoogle ScholarPubMed
Rapoport, S. I. (2014). Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. ACS Chem Neurosci, 5, 459–467.CrossRefGoogle ScholarPubMed
Akkouh, I. A., Skrede, S., Holmgren, A., et al. (2020). Exploring lithium’s transcriptional mechanisms of action in bipolar disorder: A multi-step study. Neuropsychopharmacology, 45, 947–955.CrossRefGoogle ScholarPubMed
Sharpley, A. L., Williams, C., Holder, A. A., et al. (2020). A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. Psychopharmacology (Berl), 237, 3773–3782.CrossRefGoogle ScholarPubMed
Valvassori, S. S., Cararo, J. H., Peper-Nascimento, J., et al. (2020). Protein kinase C isoforms as a target for manic-like behaviors and oxidative stress in a dopaminergic animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry, 101, doi: 10.1016/j.pnpbp.2020.109940.CrossRefGoogle Scholar
Beaulieu, J. M., Gainetdinov, R. R. and Caron, M. G. (2009). Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol, 49, 327–347.CrossRefGoogle ScholarPubMed
Beaulieu, J. M., Del’guidice, T., Sotnikova, T. D., et al. (2011). Beyond cAMP: The regulation of Akt and GSK3 by dopamine receptors. Front Mol Neurosci, 4, 38.CrossRefGoogle ScholarPubMed
Beaulieu, J. M., Marion, S., Rodriguiz, R. M., et al. (2008). A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell, 132, 125–136.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×